An inhaled Ebola vaccine has shown promise in early studies involving non-human primates.
Results of the pre-clinical study conducted at The University of Texas at Austin's College of Pharmacy were published in the online edition of the journal Molecular Pharmaceutics this week. The report noted that a non-injectable, breathable vaccine could help with the storage and transportation of the vaccine, especially in West Africa, where Ebola is rampant.
“The main advantage of our vaccine platform over the others in clinical testing is the long-lasting protection after a single inhaled dose,” UT professor Maria Croyle, co-author of the report, said. “This is important since the longevity of other vaccines for Ebola that are currently being evaluated is not fully evaluated. Moreover, this immunization method is more attractive than an injectable vaccine given the costs associated with syringe distribution and needle safety and disposal.”
Other authors of the study include UT graduate student Kristina Jonsson-Schmunk and Dr. Gary Kobinger and his team at the National Microbiology Laboratory in Winnipeg.
“There is a desperate need for a vaccine that not only prevents the continued transmission from person to person, but also aids in controlling future incidences,” Jonsson-Schmunk said.
The full findings of the study were presented at the 2014 American Association of Pharmaceutical Scientists Annual Meeting and Exposition in San Diego on Wednesday.